Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EOLS Evolus	$5.90 -2.8%	$9.25	$5.85 ▼ $17.82	$381.61M	1.12	2.08 million shs	2.72 million shs
KYTX Kyverna Therapeutics	$3.24 -2.1%	$3.40	$1.78 ▼ $8.78	$140.03M	3.05	245,955 shs	176,559 shs
PHAT Phathom Pharmaceuticals	$9.74 +3.6%	$8.81	$2.21 ▼ $19.71	$690.96M	0.45	1.05 million shs	1.37 million shs
REPL Replimune Group	$5.29 -3.5%	$8.69	$2.68 ▼ $17.00	$412.94M	0.67	24.15 million shs	4.85 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EOLS Evolus	0.00%	-35.52%	-37.76%	-40.88%	-54.48%
KYTX Kyverna Therapeutics	0.00%	-5.81%	-19.60%	+46.61%	-50.61%
PHAT Phathom Pharmaceuticals	0.00%	+16.65%	+6.10%	+209.21%	-17.11%
REPL Replimune Group	0.00%	-30.39%	-51.78%	-32.70%	-44.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EOLS Evolus	3.4608 of 5 stars	3.4	0.0	3.5	0.9	3.3	0.6
KYTX Kyverna Therapeutics	2.4025 of 5 stars	3.6	4.0	0.0	1.9	0.0	0.6
PHAT Phathom Pharmaceuticals	3.097 of 5 stars	3.5	2.0	0.0	1.6	5.0	0.6
REPL Replimune Group	4.7449 of 5 stars	4.2	4.0	4.5	2.2	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EOLS Evolus	2.80	Moderate Buy	$21.25	260.17% Upside
KYTX Kyverna Therapeutics	3.17	Buy	$15.60	381.48% Upside
PHAT Phathom Pharmaceuticals	3.00	Buy	$17.50	79.67% Upside
REPL Replimune Group	2.33	Hold	$7.67	44.93% Upside

Current Analyst Ratings Breakdown

Latest KYTX, REPL, EOLS, and PHAT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	EOLS Evolus	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $18.00
8/6/2025	EOLS Evolus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$27.00 ➝ $20.00
8/6/2025	EOLS Evolus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$22.00
7/30/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
7/23/2025	REPL Replimune Group	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$17.00 ➝ $3.00
7/23/2025	REPL Replimune Group	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Underperform	$27.00 ➝ $2.00
7/23/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/22/2025	REPL Replimune Group	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/22/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/22/2025	REPL Replimune Group	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$31.00 ➝ $6.00
7/22/2025	REPL Replimune Group	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$21.00 ➝ $3.00

(Data available from 8/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EOLS Evolus	$266.27M	1.43	N/A	N/A	$0.09 per share	65.56
KYTX Kyverna Therapeutics	$7.03M	19.92	N/A	N/A	$6.17 per share	0.53
PHAT Phathom Pharmaceuticals	$55.25M	12.51	N/A	N/A	($3.71) per share	-2.63
REPL Replimune Group	N/A	N/A	N/A	N/A	$5.40 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EOLS Evolus	-$50.42M	-$0.98	N/A	N/A	N/A	-22.31%	-759.04%	-24.63%	N/A
KYTX Kyverna Therapeutics	-$127.48M	-$3.38	N/A	N/A	N/A	N/A	-51.66%	-45.92%	8/11/2025 (Estimated)
PHAT Phathom Pharmaceuticals	-$334.33M	-$4.73	N/A	N/A	N/A	-289.51%	N/A	-90.40%	N/A
REPL Replimune Group	-$247.30M	-$3.24	N/A	N/A	N/A	N/A	-65.69%	-50.85%	8/14/2025 (Estimated)

Latest KYTX, REPL, EOLS, and PHAT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	KYTX Kyverna Therapeutics	-$1.00	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q1 2026	REPL Replimune Group	-$0.83	-$0.95	-$0.12	-$0.95	$0.50 million	N/A
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A
5/13/2025	Q1 2025	KYTX Kyverna Therapeutics	-$1.21	-$1.03	+$0.18	-$1.03	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EOLS Evolus	22.00	2.27	1.86
KYTX Kyverna Therapeutics	N/A	7.44	7.44
PHAT Phathom Pharmaceuticals	N/A	2.38	2.35
REPL Replimune Group	0.17	7.95	7.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EOLS Evolus	90.69%
KYTX Kyverna Therapeutics	18.08%
PHAT Phathom Pharmaceuticals	99.01%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
EOLS Evolus	6.10%
KYTX Kyverna Therapeutics	N/A
PHAT Phathom Pharmaceuticals	24.10%
REPL Replimune Group	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EOLS Evolus	170	64.68 million	60.74 million	Optionable
KYTX Kyverna Therapeutics	96	43.22 million	N/A	Optionable
PHAT Phathom Pharmaceuticals	110	70.94 million	53.85 million	Optionable
REPL Replimune Group	210	78.06 million	74.00 million	Optionable

KYTX, REPL, EOLS, and PHAT Headlines

Recent News About These Companies

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Replimune Group, Inc. ...

August 10 at 9:13 AM | gurufocus.com

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL

August 10 at 8:45 AM | globenewswire.com

Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REPL

August 9 at 9:51 PM | theglobeandmail.com

Replimune Group Reports Increased Losses Amid Rising R&D Costs

August 9 at 9:51 PM | theglobeandmail.com

REPL Investors Have Opportunity to Lead Replimune Group, Inc. ...

August 9 at 1:31 PM | gurufocus.com

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

August 9 at 12:47 PM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

August 9 at 10:54 AM | globenewswire.com

Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - REPL

August 9 at 7:56 AM | prnewswire.com

Shareholders of Replimune Group, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights – REPL

August 8 at 4:25 PM | globenewswire.com

Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - REPL

August 8 at 8:45 AM | prnewswire.com

Replimune Group, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before ...

August 8 at 2:28 AM | times-news.comT

Replimune (REPL) Q1 Loss Widens 61%

August 8 at 2:28 AM | aol.comA

Replimune Group: The Prospects For FDA Approval After Rejection

August 8 at 2:28 AM | seekingalpha.com

Replimune Group, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before September 22, 2025 to Discuss Your Rights – REPL

August 7, 2025 | globenewswire.com

REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 7, 2025 | globenewswire.com

ROSEN, THE FIRST FILING FIRM, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL

August 7, 2025 | globenewswire.com

Shareholders that lost money on Replimune Group, Inc. ...

August 7, 2025 | gurufocus.com

Shareholders that lost money on Replimune Group, Inc.(REPL) should contact The Gross Law Firm about pending Class Action - REPL

August 7, 2025 | prnewswire.com

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

August 7, 2025 | globenewswire.com

Replimune Group (REPL) Expected to Announce Earnings on Thursday

August 7, 2025 | marketbeat.com

Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman

August 6, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX, REPL, EOLS, and PHAT Company Descriptions

Evolus NASDAQ:EOLS

$5.90 -0.17 (-2.80%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$5.97 +0.07 (+1.19%)

As of 08/8/2025 07:49 PM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Kyverna Therapeutics NASDAQ:KYTX

$3.24 -0.07 (-2.11%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$3.27 +0.03 (+0.80%)

As of 08/8/2025 04:43 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Phathom Pharmaceuticals NASDAQ:PHAT

$9.74 +0.34 (+3.62%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$9.64 -0.10 (-0.99%)

As of 08/8/2025 07:00 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Replimune Group NASDAQ:REPL

$5.29 -0.19 (-3.47%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$5.19 -0.10 (-1.89%)

As of 08/8/2025 07:59 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time